A PYMNTS Company

US/Japan: Astellas agrees to last-minute drug monopoly settlement

By  |  January 21, 2015

Japan-based pharmaceutical company Astellas Pharma Inc. agreed to settle an antitrust lawsuit ahead of trial, which was set to begin last Tuesday in Boston federal court. The Louisiana Wholesale Drug Co. and other plaintiffs had filed five lawsuits against Astellas in 2011 accusing it of illegally holding a monopoly on the market for Tacrolimus, sold under the brand name Prograf.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The allegations claimed Astellas made tactical efforts to keep the generic version of the anti-rejection, immune-suppressant drug off store shelves. Specifically, plaintiffs argued that Astellas filed a “sham” petition in 2007 seeking safety and efficacy test for the generic version of the drug in efforts to delay its entry onto the market. Details of the settlement were not disclosed.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.